23 June 2016 - Research shows Simponi improves symptoms and physical function.

Janssen today announced Health Canada has approved Simponi (golimumab) for the treatment of adults with severe active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence who have had an inadequate response to or are intolerant to nonsteroidal anti-inflammatory drugs.

This is the fifth indication for Simponi in Canada, which was approved originally by Health Canada in 2009 for adults living with moderately to severely active rheumatoid arthritis.

For more detaiks, go to: http://www.newswire.ca/news-releases/health-canada-issues-a-notice-of-compliance-for-simponi-as-the-first-and-only-treatment-indicated-for-non-radiographic-axial-spondyloarthritis-584180171.html